These PCT patent documents covering potential treatments, diagnostics, or animal and cell culture models for rare diseases as a central theme have been extracted from the WIPO PatentScope database. Abstracts are as published. This a free H. M. Pharma Consultancy service; please cite it if you use it as a starting point for your own research. Nothing in this post should be constructed as represent...

These PCT patent documents covering potential treatments, diagnostics, or animal and cell culture models for rare diseases as a central theme have been extracted from the WIPO PatentScope database. Abstracts are as published. This a free H. M. Pharma Consultancy service; please cite it if you use it as a starting point for your own research. Nothing in this post should be constructed as represent...

These PCT patent documents covering potential treatments, diagnostics, or animal and cell culture models for rare diseases as a central theme have been extracted from the WIPO PatentScope database. Abstracts are as published. This a free H. M. Pharma Consultancy service; please cite it if you use it as a starting point for your own research. Nothing in this post should be constructed as represent...

2020… Ah, what a ride. And no, this is not another text piece joining the chorus of weeping, complaining, and interpreting how the Covid-19 pandemic has devastated drug developers – except those who had an approved antiviral drug available that had some effect against SARS-CoV2. And of course, except those who suddenly fell in love with drug repurposing and actually identified a marketed drug ...

We continue our series with a summary of the Q1/2019 drug repurposing patent discussions in ASSAY and Drug Development Technologies (ahead of print, DOI link here).   WO/2019/004808 (Université Mohammed V Rabat (Morocco) Pyridostigmin restores peripheral nervous system balance in neurodegenerative diseases or after neurotrauma WO/2019/008141 INSERM, CNRS, Université Paris Descarte...

Long time no post here. Still no narrative blogpost b/c virtually all our activities are client-confidential – sorry. But here is a synopsis of the drug repurposing patent discussions that you can soon read in full, in ASSAY and Drug Development Technologies. We shall start with documents published during Q4/2018. Remember, this is only a selection – there are many more that are interesting but di...

This is what to look for in the December 2018 issue of ASSAY and Drug Development Technologies: WO/2018/126000 (Rush University Medical Center, USA) Fibrates (in particular, gemfibrozil) are claimed for LINCL Type 2, a subtype of Batten disease. Much prior art here, some of it ffrom the inventors themselves. WO/2018/126192 (Childrens’ Medical Center Corp., USA) Congenital arteriovenous malform...

Along the lines that have been discussed in a recent Frontiers short paper, here is a list of our patent discussions in the December 2017 drug repurposing special issue of ASSAY and Drug Development Technologies: WO/2017/059389 (Kythera Biopharmaceuticals, USA): Statins as an alternative to liposuction and cryolipolysis WO/2017/060308 (AB Science, France): Masitinib switches to human use WO/201...